Advertisement

Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer

Published:October 31, 2017DOI:https://doi.org/10.1016/j.ejca.2017.10.002

      Highlights

      • This study was a prospective randomized phase II, multicentre study comparing EG with PG for MBC patients.
      • The 6-month PFS rates for both arms were 72% for EG and 73% for PG (P = 0.457).
      • EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of progression-free survival but less neurotoxicity.

      Abstract

      Background

      Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin mesylate is a halichondrin non-taxane inhibitor of microtubule dynamics. A recent pooled analysis with eribulin showed improved overall survival (OS) in various MBC patient subgroups pretreated with anthracycline and taxane. Furthermore, eribulin may have less neurotoxicity than paclitaxel.

      Patients and methods

      This study was a prospective randomised phase II, open-label, two-arm, multicentre study comparing eribulin plus gemcitabine (EG) with PG chemotherapy as a first-line treatment for patients with human epidermal growth factor receptor 2-negative MBC. We hypothesised that EG chemotherapy would not be inferior to PG chemotherapy. The primary end-point was progression-free survival (PFS), which was estimated to be 70% at 6 months for each arm. The secondary end-points were as follows: OS, neuropathic scale, toxicity and clinical benefit rate.

      Results

      A total of 118 patients (median age: 50, 24–66) were enrolled between March 2015 and March 2016 and were randomly assigned to PG (n = 59) or EG (n = 59) chemotherapy. The mean number of metastatic sites was 3 (range 1–8). The 6-month PFS rates for both arms were 72% for EG and 73% for PG (P = 0.457). There was no significant difference in OS between the two groups (not reached versus 21.2 months, P = 0.2234). The median number of chemotherapy cycles for both groups was 10 for EG and 8 for PG (range 2–32). Clinical benefit rates were 44% for EG and 49% for PG. Major toxicities were neutropenia and neurotoxicity. Grade II or above neurotoxicity was more common with PG than with EG (13.6% for EG versus 45.8% for PG, P < 0.0001).

      Conclusion

      EG chemotherapy had similar clinical benefits to PG chemotherapy in terms of PFS but less neurotoxicity.

      Trial registration

      KCSG BR13-11; ClinicalTrials.gov, NCT02263495.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA Cancer J Clin. 2017; 67: 7-30
        • Jung K.W.
        • Won Y.J.
        • Oh C.M.
        • Kong H.J.
        • Lee D.H.
        • Lee K.H.
        • et al.
        Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014.
        Cancer Res Treat. 2017; 49: 292-305
        • Bonotto M.
        • Gerratana L.
        • Iacono D.
        • Minisini A.M.
        • Rihawi K.
        • Fasola G.
        • et al.
        Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?.
        Oncologist. 2015; 20: 719-724
        • Kuznetsov G.
        • Towle M.J.
        • Cheng H.
        • Kawamura T.
        • TenDyke K.
        • Liu D.
        • et al.
        Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
        Cancer Res. 2004; 64: 5760-5766
        • Smith J.A.
        • Wilson L.
        • Azarenko O.
        • Zhu X.
        • Lewis B.M.
        • Littlefield B.A.
        • et al.
        Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability.
        Biochemistry. 2010; 49: 1331-1337
        • Jordan M.A.
        • Kamath K.
        • Manna T.
        • Okouneva T.
        • Miller H.P.
        • Davis C.
        • et al.
        The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth.
        Mol Cancer Ther. 2005; 4: 1086-1095
        • Pivot X.
        • Marme F.
        • Koenigsberg R.
        • Guo M.
        • Berrak E.
        • Wolfer A.
        Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
        Ann Oncol. 2016; 27: 1525-1531
        • Kuznetsov G.
        • Xu Q.
        • Rudolph-Owen L.
        • Tendyke K.
        • Liu J.
        • Towle M.
        • et al.
        Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A.
        Mol Cancer Ther. 2009; 8: 1250-1260
        • Towle M.J.
        • Salvato K.A.
        • Budrow J.
        • Wels B.F.
        • Kuznetsov G.
        • Aalfs K.K.
        • et al.
        In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B.
        Cancer Res. 2001; 61: 1013-1021
        • Albain K.S.
        • Nag S.M.
        • Calderillo-Ruiz G.
        • Jordaan J.P.
        • Llombart A.C.
        • Pluzanska A.
        • et al.
        Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
        J Clin Oncol. 2008; 26: 3950-3957
        • Park Y.H.
        • Jung K.H.
        • Im S.A.
        • Sohn J.H.
        • Ro J.
        • Ahn J.H.
        • et al.
        Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
        J Clin Oncol. 2013; 31: 1732-1739
        • Wozniak K.M.
        • Nomoto K.
        • Lapidus R.G.
        • Wu Y.
        • Carozzi V.
        • Cavaletti G.
        • et al.
        Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice.
        Cancer Res. 2011; 71: 3952-3962
        • Lheureux S.
        • Oza A.M.
        • Laurie S.A.
        • Halford R.
        • Jonker D.
        • Chen E.
        • et al.
        A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
        Br J Cancer. 2015; 113: 1534-1540
        • Therasse P.
        • Le Cesne A.
        • Van Glabbeke M.
        • Verweij J.
        • Judson I.
        RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
        Eur J Cancer. 2005; 41: 1426-1430
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Cella D.F.
        • Tulsky D.S.
        • Gray G.
        • Sarafian B.
        • Linn E.
        • Bonomi A.
        • et al.
        The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
        J Clin Oncol. 1993; 11: 570-579
        • Jung S.H.
        Design of phase II non-inferiority trials.
        Contemp Clin Trials Commun. 2017; 7: 23-27
        • Wandel S.
        • Neuenschwander B.
        • Rover C.
        • Friede T.
        Using phase II data for the analysis of phase III studies: an application in rare diseases.
        Clin Trials. 2017; 14: 277-285
        • Gennari A.
        • D'Amico M.
        • Corradengo D.
        Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.
        Ther Adv Med Oncol. 2011; 3: 229-232
        • Wandel S.
        • Neuenschwander B.
        • Rover C.
        • Friede T.
        Using phase II data for the analysis of phase III studies: an application in rare diseases.
        Clin Trials. 2017; 14 (1740774517699409)
        • Andre F.
        • Neven P.
        • Marinsek N.
        • Zhang J.
        • Baladi J.F.
        • Degun R.
        • et al.
        Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer.
        Curr Med Res Opin. 2014; 30: 1007-1016
        • Bonotto M.
        • Gerratana L.
        • Di Maio M.
        • De Angelis C.
        • Cinausero M.
        • Moroso S.
        • et al.
        Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis.
        Breast. 2017; 31: 114-120